71 research outputs found
The effect of functional splinting on mild dysplastic hips after walking onset
BACKGROUND: For treatment of Graf class IIb dysplastic hips at walking onset a treatment concept with abduction splints allowing patterns as walking and crawling under constant abduction control was investigated. However, as the splint still incapacitates child movements the research question remains whether the physiologically progressing maturation of hips can be significantly altered using such abduction splints for walking children. METHODS: Of 106 children showing late hip dysplasia, 68 children treated with the Hoffman-Daimler (HD-splint) abduction splint were compared with 38 children with neglect of the abduction treatment in this retrospective study. Radiographic analyses were performed measuring the development of the age dependent acetabular angle. RESULTS: The regression analysis for splint treatment showed a significant linear regression for both splint treatment and no splint treatment group (r(2 )= 0,31 respectively r(2 )= 0,33). No statistical difference between both treatment groups was apparent. CONCLUSION: Considering the characteristics of this study, there seems to be no strong rationale supporting the use of an abduction device in growing children. As no significant difference between treatment groups is apparent, a future controlled prospective study on splinting effects can be considered ethically allowed
Sampling-based Algorithms for Optimal Motion Planning
During the last decade, sampling-based path planning algorithms, such as
Probabilistic RoadMaps (PRM) and Rapidly-exploring Random Trees (RRT), have
been shown to work well in practice and possess theoretical guarantees such as
probabilistic completeness. However, little effort has been devoted to the
formal analysis of the quality of the solution returned by such algorithms,
e.g., as a function of the number of samples. The purpose of this paper is to
fill this gap, by rigorously analyzing the asymptotic behavior of the cost of
the solution returned by stochastic sampling-based algorithms as the number of
samples increases. A number of negative results are provided, characterizing
existing algorithms, e.g., showing that, under mild technical conditions, the
cost of the solution returned by broadly used sampling-based algorithms
converges almost surely to a non-optimal value. The main contribution of the
paper is the introduction of new algorithms, namely, PRM* and RRT*, which are
provably asymptotically optimal, i.e., such that the cost of the returned
solution converges almost surely to the optimum. Moreover, it is shown that the
computational complexity of the new algorithms is within a constant factor of
that of their probabilistically complete (but not asymptotically optimal)
counterparts. The analysis in this paper hinges on novel connections between
stochastic sampling-based path planning algorithms and the theory of random
geometric graphs.Comment: 76 pages, 26 figures, to appear in International Journal of Robotics
Researc
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer
Introduction: In developed countries, ovarian cancer is the fourth most common cancer in women. Due to the nonspecific symptomatology associated with the disease many patients with ovarian cancer are diagnosed late, which leads to significantly poorer prognosis. Apart from surgery and radiotherapy, a substantial number of ovarian cancer patients will undergo chemotherapy and platinum based agents are the mainstream first-line therapy for this disease. Despite the initial efficacy of these therapies, many women relapse; therefore, strategies for second-line therapies are required. Regulation of DNA transcription is crucial for tumour progression, metastasis and chemoresistance which offers potential for novel drug targets. Methods: We have reviewed the existing literature on the role of histone deacetylases, nuclear enzymes regulating gene transcription. Results and conclusion: Analysis of available data suggests that a signifant proportion of drug resistance stems from abberant gene expression, therefore HDAC inhibitors are amongst the most promising therapeutic targets for cancer treatment. Together with genetic testing, they may have a potential to serve as base for patient-adapted therapies
Two Naturally Occurring Terpenes, Dehydrocostuslactone and Costunolide, Decrease Intracellular GSH Content and Inhibit STAT3 Activation
The main purpose of the present study is to envisage the molecular mechanism of
inhibitory action ofdehydrocostuslactone (DCE) andcostunolide (CS), two
naturally occurring sesquiterpene lactones, towards the activation of signal
transducer and activator of transcription 3 (STAT3). We report that, in human
THP-1 cell line, they inhibit IL-6-elicited tyrosine phosphorylation of STAT3
and its DNA binding activity with EC50 of 10 µM with
concomitantdown-regulation ofthe phosphorylation of the tyrosine Janus kinases
JAK1, JAK2 and Tyk2. Furthermore, these compounds that contain an
α-β-unsatured carbonyl moiety and function as potent Michael reaction
acceptor, induce a rapid drop in intracellular glutathione (GSH) concentration
by direct interaction with it, thereby triggering
S-glutathionylation of STAT3. Dehydrocostunolide (HCS), the
reduced form of CS lacking only the α-β-unsaturated carbonyl group,
fails to exert any inhibitory action. Finally, the glutathione ethylene ester
(GEE), the cell permeable GSH form, reverts the inhibitory action of DCE and CS
on STAT3 tyrosine phosphorylation. We conclude that these two sesquiterpene
lactones are able to induce redox-dependent post-translational modification of
cysteine residues of STAT3 protein in order to regulate its function
Reconstitution of the Costunolide Biosynthetic Pathway in Yeast and Nicotiana benthamiana
The sesquiterpene costunolide has a broad range of biological activities and is the parent compound for many other biologically active sesquiterpenes such as parthenolide. Two enzymes of the pathway leading to costunolide have been previously characterized: germacrene A synthase (GAS) and germacrene A oxidase (GAO), which together catalyse the biosynthesis of germacra-1(10),4,11(13)-trien-12-oic acid. However, the gene responsible for the last step toward costunolide has not been characterized until now. Here we show that chicory costunolide synthase (CiCOS), CYP71BL3, can catalyse the oxidation of germacra-1(10),4,11(13)-trien-12-oic acid to yield costunolide. Co-expression of feverfew GAS (TpGAS), chicory GAO (CiGAO), and chicory COS (CiCOS) in yeast resulted in the biosynthesis of costunolide. The catalytic activity of TpGAS, CiGAO and CiCOS was also verified in planta by transient expression in Nicotiana benthamiana. Mitochondrial targeting of TpGAS resulted in a significant increase in the production of germacrene A compared with the native cytosolic targeting. When the N. benthamiana leaves were co-infiltrated with TpGAS and CiGAO, germacrene A almost completely disappeared as a result of the presence of CiGAO. Transient expression of TpGAS, CiGAO and CiCOS in N. benthamiana leaves resulted in costunolide production of up to 60 ng.g−1 FW. In addition, two new compounds were formed that were identified as costunolide-glutathione and costunolide-cysteine conjugates
Pan-cancer analysis of whole genomes
Cancer is driven by genetic change, and the advent of massively parallel sequencing has enabled systematic documentation of this variation at the whole-genome scale(1-3). Here we report the integrative analysis of 2,658 whole-cancer genomes and their matching normal tissues across 38 tumour types from the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). We describe the generation of the PCAWG resource, facilitated by international data sharing using compute clouds. On average, cancer genomes contained 4-5 driver mutations when combining coding and non-coding genomic elements; however, in around 5% of cases no drivers were identified, suggesting that cancer driver discovery is not yet complete. Chromothripsis, in which many clustered structural variants arise in a single catastrophic event, is frequently an early event in tumour evolution; in acral melanoma, for example, these events precede most somatic point mutations and affect several cancer-associated genes simultaneously. Cancers with abnormal telomere maintenance often originate from tissues with low replicative activity and show several mechanisms of preventing telomere attrition to critical levels. Common and rare germline variants affect patterns of somatic mutation, including point mutations, structural variants and somatic retrotransposition. A collection of papers from the PCAWG Consortium describes non-coding mutations that drive cancer beyond those in the TERT promoter(4); identifies new signatures of mutational processes that cause base substitutions, small insertions and deletions and structural variation(5,6); analyses timings and patterns of tumour evolution(7); describes the diverse transcriptional consequences of somatic mutation on splicing, expression levels, fusion genes and promoter activity(8,9); and evaluates a range of more-specialized features of cancer genomes(8,10-18).Peer reviewe
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Tyrosine kinases are important cellular signaling proteins that have a variety of biological activities including cell proliferation and migration. Multiple kinases are involved in angiogenesis, including receptor tyrosine kinases such as the vascular endothelial growth factor receptor. Inhibition of angiogenic tyrosine kinases has been developed as a systemic treatment strategy for cancer. Three anti-angiogenic tyrosine kinase inhibitors (TKIs), sunitinib, sorafenib and pazopanib, with differential binding capacities to angiogenic kinases were recently approved for treatment of patients with advanced cancer (renal cell cancer, gastro-intestinal stromal tumors, and hepatocellular cancer). Many other anti-angiogenic TKIs are being studied in phase I-III clinical trials. In addition to their beneficial anti-tumor activity, clinical resistance and toxicities have also been observed with these agents. In this manuscript, we will give an overview of the design and development of anti-angiogenic TKIs. We describe their molecular structure and classification, their mechanism of action, and their inhibitory activity against specific kinase signaling pathways. In addition, we provide insight into what extent selective targeting of angiogenic kinases by TKIs may contribute to the clinically observed anti-tumor activity, resistance, and toxicity. We feel that it is of crucial importance to increase our understanding of the clinical mechanism of action of anti-angiogenic TKIs in order to further optimize their clinical efficacy
- …